Evergy (NYSE:EVRG – Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $3.73-3.93 for the period, compared to the consensus EPS estimate of $3.84. Evergy also updated its FY 2024 guidance to 3.730-3.930 EPS. Wall Street Analyst Weigh In EVRG has been the subject […]

Intact Financial (TSE:IFC – Free Report) had its target price hoisted by Raymond James from C$264.00 to C$290.00 in a research report report published on Wednesday, BayStreet.CA reports. Raymond James also issued estimates for Intact Financial’s Q4 2024 earnings at $4.64 EPS, Q1 2025 earnings at $4.57 EPS and Q4 2025 earnings at $4.97 EPS. […]

Axcelis Technologies (NASDAQ:ACLS – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.250-1.250 for the period, compared to the consensus estimate of 1.520. The company issued revenue guidance of $245.0 million-$245.0 million, compared to the consensus revenue estimate […]

The Pennant Group (NASDAQ:PNTG – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.900-0.960 for the period, compared to the consensus earnings per share estimate of 0.910. The company issued revenue guidance of $665.3 million-$706.5 million, compared to the consensus revenue estimate of $679.3 […]

Astera Labs (NASDAQ:ALAB – Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.250-0.260 for the period, compared to the consensus estimate of 0.180. The company issued revenue guidance of $126.0 million-$130.0 million, compared to the consensus revenue estimate of $108.4 million. Astera […]

Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – Stock analysts at Wedbush upped their FY2024 earnings per share estimates for shares of Disc Medicine in a research note issued on Monday, November 4th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($3.92) per share for the year, up from their […]